Storage Beyond Limit: Hoymiles Drives the Future of Energy Storage at Intersolar Europe 2025
MUNICH, May 11, 2025 /CNW/ -- Hoymiles, a global provider of smart solar and storage solutions, made a striking appearance at Intersolar Europe 2025 with its comprehensive energy storage portfolio, covering DIY micro storage, residential, commercial & industrial (C&I), and utility-scale applications. Under the theme "Storage Beyond Limit. Micro to Mega, All In Smart", Hoymiles highlights its latest C&I storage innovations including Power Conversion Systems and Containerized Battery Energy Storage Systems, marking a major milestone in its strategic transformation towards energy storage.
Storage Beyond Limit: Hoymiles Drives the Future of Energy Storage at Intersolar Europe 2025
At the heart of Hoymiles' exhibition was its next-generation commercial and industrial storage lineup, led by the new HoyUltra2 series (HESS-261-2h). Engineered for maximum performance and reliability, HoyUltra2 features a fully liquid cooling system for both battery and PCS, enabling full-capacity operation without derating even at 50°C ambient temperature and 3,000m altitude.
With a maximum round-trip efficiency of 90.3% and a three-level, six-type safety protection mechanism, it ensures 24/7 secure and intelligent operations. The Edge EMS enables local optimization, the cloud-based analytics provide deep system insights, and a user-friendly local app simplifies O&M tasks. With quiet 60dB operation and IP55-rated protection, HoyUltra2 is ideal for supermarkets, hotels, residential communities, and other sensitive environments.
High-efficiency and safe large-scale storage: HoyPrime series
Hoymiles introduced its HoyPrime containerized storage solutions, with 1 MW/2 MWh options for large C&I projects and 3.44 MWh for utility-scale applications. Designed for high energy density, efficiency, and cost-effectiveness, HoyPrime features intelligent liquid cooling to minimize auxiliary power use and extend lifespan. Its compact, non-walk-in design reduces footprint while maximizing capacity. Standardized interfaces and automated maintenance simplify deployment and O&M. Certified to IEC and UL standards, HoyPrime is already powering projects worldwide, reinforcing Hoymiles' global energy storage leadership.
Powering the sustainable future with full-spectrum energy innovations
Alongside its latest C&I storage innovations, Hoymiles also showcased a full microinverter lineup—including the MS-A2 Micro Storage, 5,000 W 8-in-1 MiT series, HMS series, and three-phase HMT series. From residential to utility-scale solutions, Hoymiles delivers smart, scalable technologies for all scenarios.
Looking ahead, Hoymiles will continue advancing full-spectrum energy solutions and, together with its partners, drive a cleaner, smarter energy future. By strengthening Europe's energy security, enhancing grid resilience, and promoting global sustainability, Hoymiles is playing a key role in shaping a more resilient and sustainable world.
Learn more at https://www.hoymiles.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/storage-beyond-limit-hoymiles-drives-the-future-of-energy-storage-at-intersolar-europe-2025-302451864.html
SOURCE Hoymiles Power Electronic Inc
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2025/11/c0807.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
MustGrow Biologics Corp (MGROF) Q1 2025 Earnings Call Highlights: A Promising Start with ...
Sales Revenue: $3.8 million for Q1 2025. Gross Profit: Approximately $540,000. Gross Margin: 14.3%. Cash Position: $2 million. NexusBioAg Sales: Historical sales between $15 million to $20 million, with expectations to maintain this range. Shares Outstanding: 52 million shares, 59 million fully diluted. Warning! GuruFocus has detected 5 Warning Signs with MGROF. Release Date: May 28, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. MustGrow Biologics Corp (MGROF) reported $3.8 million in sales revenue for Q1 2025, marking a significant milestone as their initial sales numbers. The company successfully integrated NexusBioAg, a sales and distribution division, which contributed to the Q1 sales. MustGrow Biologics Corp (MGROF) has a strong partnership with Bayer, which includes a commercial agreement in Europe, Middle East, and Africa, with potential for milestone and royalty payments. The company holds 112 patents, showcasing a robust intellectual property portfolio, and is actively working on new IP generation. MustGrow Biologics Corp (MGROF) is focusing on a high-growth, asset-light model, with a tight capital structure and plans to drive revenue and margin growth. The gross margin for Q1 2025 was 14.3%, which was negatively affected by foreign exchange fluctuations and tariffs. Sales for TerraSante have not yet ramped up significantly, with expectations for more meaningful sales in late 2025 or early 2026. The company faces challenges with the registration process for TerraMG, with potential registration not expected until 2026. MustGrow Biologics Corp (MGROF) is assessing the need for additional working capital to drive revenue growth, indicating potential financial constraints. The agricultural market's seasonality and cyclicality present challenges in sales predictability and revenue generation. Q: Sales so far were all from Canada, right? Were any of them from TerraSante? A: Yes, Q1 sales were all in Canada, specifically through NexusBioAg. TerraSante sales in the US are expected to ramp up in the second half of this year. Q: How have tariffs affected sales, specifically for TerraSante? A: Our products were not directly affected by tariffs, but there were indirect effects such as a weaker Canadian dollar, which negatively impacted margins. Q: Are you able to provide any sort of a forecast for TerraSante? A: No, we do not provide forecasts at this time. Q: Is the regenerative or natural input market for agriculture growing faster than traditional inputs? A: Yes, the regenerative agriculture market is growing at a significant double-digit CAGR compared to the single-digit growth of the synthetic market. Q: When do you expect to see positive free cash flow? A: Our goal is to achieve positive cash flows next year, potentially into 2027, by driving revenues and margins. Q: Do you need more working capital for inventory to drive your revenues? A: Yes, we are assessing access to capital, including non-dilutive options, to support revenue and margin growth. Q: Are there any updates on the registration process for TerraMG? A: In North America, we are progressing with registrations and hope to have them by 2026. Bayer is also working on registrations in Europe, the Middle East, and Africa. Q: Does NexusBioAg only focus on Western Canada, or do they have a presence in Eastern Canada as well? A: NexusBioAg has coverage across Canada, with significant operations in both Western and Eastern Canada. Q: Are there any more impactful products in the pipeline to run through Nexus? A: Yes, there are many products in the pipeline, and we are leveraging Nexus's market access and relationships to introduce them. Q: Is there a push to open up or get approval in more US states? A: Currently, we are focusing on accelerating sales in California, Washington, Oregon, and Idaho, with potential expansion to other states being assessed. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Quanex Building Products Corp (NX) Q2 2025 Earnings Call Highlights: Record Sales Surge and ...
Net Sales: $452.2 million in Q2 2025, up 70% from $266.2 million in Q2 2024. Net Income: $20.5 million or $0.44 per diluted share in Q2 2025; adjusted net income of $27.9 million or $0.60 per diluted share. Adjusted EBITDA: Increased by 54.7% to $61.9 million in Q2 2025 from $40 million in Q2 2024. North American Fenestration Segment Sales: $151 million in Q2 2025, a decrease of 5.5% from $159.8 million in Q2 2024. European Fenestration Segment Sales: $61.3 million in Q2 2025, up 8.3% from $56.5 million in Q2 2024. North American Cabinet Component Segment Sales: $51.2 million in Q2 2025, compared to $51.1 million in Q2 2024. Tyman Business Sales: $190.1 million in Q2 2025. Cash Flow from Operations: $28.5 million in Q2 2025, compared to $33.1 million in Q2 2024. Free Cash Flow: $13.6 million in Q2 2025. Leverage Ratio: Net debt to last 12 months adjusted EBITDA at 3.2 times; debt covenant leverage ratio at 2.7 times. Share Repurchase: Approximately $23.5 million of stock repurchased in Q2 2025. Cost Synergies: Expected to realize $45 million over time, a 50% increase from the original target. Guidance: Reaffirmed net sales guidance of $1.84 billion to $1.86 billion and adjusted EBITDA guidance of $270 million to $280 million for fiscal 2025. Warning! GuruFocus has detected 3 Warning Signs with NX. Release Date: June 06, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Quanex Building Products Corp (NYSE:NX) reported a significant increase in net sales, reaching $452.2 million in Q2 2025, a 70% rise compared to the same period in 2024, primarily driven by the Tyman acquisition. The integration of the Tyman acquisition is progressing well, with cost synergies expected to reach $45 million, a 50% increase from the original target. The company has successfully localized supply chains to mitigate tariff impacts, with 22% of total cost of goods sold exposed to tariff risk, but USMCA compliance reduces this risk for Mexico and Canada. Quanex Building Products Corp (NYSE:NX) repurchased approximately $23.5 million of its stock in Q2 2025, taking advantage of a low share price and maintaining a healthy balance sheet. The company reaffirmed its net sales guidance of $1.84 billion to $1.86 billion and adjusted EBITDA guidance of $270 million to $280 million for fiscal 2025, indicating confidence in future performance. Despite the overall sales increase, net sales excluding the Tyman contribution declined by 1.4% in Q2 2025, largely due to lower volume in North America. The North American fenestration segment saw a 5.5% decrease in net sales, with volumes declining by approximately 7% year over year. Consumer confidence in North America and Europe is negatively impacted by higher interest rates and geopolitical tensions, affecting market conditions. Pricing pressures continue in Europe, although operational performance has helped offset price concessions. Free cash flow was impacted by one-time items related to integration costs and achieving cost synergies, resulting in $13.6 million for the quarter. Q: Can you give a little more color on raising the synergy target from $30 million to $45 million, and is there potential beyond that? A: George Wilson, CEO, explained that the increase in synergy targets is due to the efficiency and opportunities identified in the new operating segments. These include headcount reductions and sourcing synergies. While revenue synergies are still early, the team is confident in further potential as they continue to refine their strategies. Q: Is the tariff situation an opportunity for Quanex given your domestic manufacturing footprint, and are you seeing bids related to increased domestic sourcing? A: George Wilson, CEO, noted that their structured supply chain and diverse geographic footprint have indeed provided opportunities. They have seen increased quoting and execution of spot purchases, particularly in the cabinet segment, as customers seek to mitigate supply chain risks. Q: Where in the Tyman portfolio have you realized cost synergies faster than expected? A: Scott Zuehlke, CFO, highlighted that the main synergies came from procurement and corporate functions such as finance, HR, and IT. The integration of teams revealed more opportunities than initially estimated. Q: Is the $6.5 million in intangible asset amortization realized in Q2 a good quarterly run rate, and what is the full-year expectation for D&A? A: Scott Zuehlke, CFO, confirmed that the Q2 figure is a reasonable run rate. The company initially guided around $60 million for adjusted D&A for the year, excluding intangible amortization, which remains a good estimate. Q: Can you provide more details on the impact of tariffs on your cost of goods sold? A: George Wilson, CEO, stated that approximately 22% of their total cost of goods sold is exposed to tariff risk, with 13% specific to Mexico and Canada. However, being USMCA compliant, the tariff rate is essentially zero for these countries, minimizing potential margin impacts. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
an hour ago
- Yahoo
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory
We came across a bullish thesis on Coherus BioSciences, Inc. (CHRS) on Steve Wagner's Substack. In this article, we will summarize the bulls' thesis on CHRS. Coherus BioSciences, Inc. (CHRS)'s share was trading at $0.77 as of 30th May. CHRS's trailing P/E was 1.77 according to Yahoo Finance. Scientist in a lab working on a research project, focusing on biotechnology and healthcare advancements. Coherus BioSciences (CHRS), long overlooked by Wall Street, is taking a bold step into innovative oncology by partnering with UK-based STORM Therapeutics to test a novel cancer treatment strategy. The collaboration brings together Coherus's immunotherapy toripalimab (LOQTORZI) and STORM's first-in-class RNA-modifying enzyme inhibitor STC-15 in a Phase 1b/2 clinical trial. This unexpected pairing represents a fresh approach to immuno-oncology, targeting cancer through dual mechanisms that could produce synergistic effects. Toripalimab, already approved in the U.S. for nasopharyngeal carcinoma and under review for broader indications, offers proven checkpoint inhibition, while STC-15 introduces a cutting-edge method of disrupting RNA methylation processes linked to tumor growth and immune evasion. If this combo demonstrates efficacy, it could represent a completely new class of cancer therapy and place Coherus at the forefront of next-generation immuno-oncology innovation. Importantly, this partnership shows strategic vision from CHRS's management as they seek to differentiate the company beyond biosimilars and move deeper into proprietary immunotherapy. With the trial still in early stages and little market attention so far, the risk/reward profile for investors is potentially skewed to the upside. Should the data prove positive, the impact could be significant for both companies, especially for CHRS as it repositions itself as a serious player in oncology innovation. This under-the-radar development deserves close monitoring, as it could catalyze a major reevaluation of Coherus's valuation and growth trajectory. Previously, we have covered CHRS in March 2025 wherein we summarized a by the same author. Coherus BioSciences (CHRS) posted a strong turnaround in 2024 with $267M in revenue and $28.5M net income, driven by Loqtorzi's growth and the planned $250M Udenyca divestiture. The company pivoted fully to oncology, trimmed costs, and advanced its pipeline, yet management expressed frustration over the stock's undervaluation, hinting at potential M&A. Since our last coverage, the stock is down 38% as of 30th May. We don't trust CHRS' management as the stock lost more than 95% of its value in recent years and is still losing a ton of money. The market agrees with us and thinks this stock is going to go bankrupt. We believe CHRS should stop wasting shareholder's money, sell valuable assets, and liquidate the company. We don't think that's a likely outcome. Coherus BioSciences, Inc. (CHRS) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 10 hedge fund portfolios held CHRS at the end of the first quarter which was 10 in the previous quarter. While we acknowledge the potential of CHRS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
